Management of immune thrombocytopenic purpura: An Update

Ochsner Journal

Volumn 12, Issue 3, 2012, Pages 221-227

  Warrier, Rajasekharan ^a   Chauhan, Aman ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immune; Purpura; Thrombocytopenia

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PENICILLIN G; PREDNISONE; RHESUS D ANTIBODY; RITUXIMAB;

ANTIGEN PRESENTING CELL; ASEPTIC MENINGITIS; AVASCULAR NECROSIS; B LYMPHOCYTE; BLOOD SMEAR; CHILL; CLINICAL FEATURE; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EOSINOPHILIA; EPISTAXIS; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; GASTRITIS; GROWTH RETARDATION; HEMOLYSIS; HEPATOSPLENOMEGALY; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; INSOMNIA; KIDNEY FAILURE; LYMPHADENOPATHY; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SPLENECTOMY; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; TUBERCULOSIS; ULCER;

EID: 84866491758     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007 Sep;14(5): 515-519.
2. Cines DB, Bussel JB, McMillan RB, Zehnder JL. Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2004:390-406. Erratum in: Hematology Am Soc Hematol Educ Program. 2005:543.
3. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951 Jul;38(1):1-10.
4. Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci. 1965 Jun 30;124(2):499-542.
5. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am. 2008 Apr;55(2):393-420.
6. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007 Oct;44(4 Suppl 5):S3-S11.
7. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR; Intercontinental Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001 Dec 22-29; 358(9299):2122-2125.
8. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 1997 Aug 30; 350(9078):620-623.
9. Sutor AH, Harms A, Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Semin Thromb Hemost. 2001 Jun;27(3):253-267.
10. Rosthj S, Hedlund-Treutiger I, Rajantie J, et al; NOPHO ITP Working Group. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: a prospective Nordic study of an unselected cohort. J Pediatr. 2003 Sep 143(3):302-307.
11. Choi SI, McClure PD. Idiopathic thrombocytopenic purpura in childhood. Can Med Assoc J. 1967 Sep 9;97(11):562-568.
12. Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. J Pediatr. 1966 Jun;68(6):971-979.
13. Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc. 1984 Feb;59(2):123-125.
14. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood. 2004 Jan 15;103(2):390-398. Epub 2003 Sep 22.
15. Sartorius JA. Steroid treatment of idiopathic thrombocytopenic purpura in children. Preliminary results of a randomized cooperative study. Am J Pediatr Hematol Oncol. 1984 Summer; 6(2):165-169.
16. Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol. 1984 Winter;6(4):355-361.
17. Sandler SG, Tutuncuoglu SO. Immune thrombocytopenic purpura-current management practices. Expert Opin Pharmacother. 2004 Dec;5(12):2515-2527.
18. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 Jul 1;88(1):3-40.
19. Ozsoylu S, Sayli TR, Oztürk G. Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 1993 Oct-Dec;10(4):317-321.
20. Suarez CR, Rademaker D, Hasson A, Mangogna L. High-dose steroids in childhood acute idiopathic thrombocytopenia purpura. Am J Pediatr Hematol Oncol. 1986 Summer;8(2):111-115.
21. van Hoff J, Ritchey AK. Pulse methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura. J Pediatr. 1988 Sep;113(3):563-566.
22. Jayabose S, Patel P, Inamdar S, Brilliant R, Mamtani R. Use of intravenous methylprednisolone in acute idiopathic thrombocytopenic purpura. Am J Pediatr Hematol Oncol. 1987 Summer;9(2):133-135.
23. Carcao MD, Zipursky A, Butchart S, Leaker M, Blanchette VS. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl. 1998 Jun;424:71-74.
24. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981 Jun 6;1(8232):1228-1231.
25. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001 Jan 19;291(5503):484-486.
26. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 2002 Sep 15; 100(6):2087-2093.
27. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993 Dec; 123(6):989-995.
28. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994 Sep 10;344(8924):703-707.
29. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983 Jul 23;2(8343):193-195.
30. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004 Apr;79(4):504-522.
31. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002 Mar 28;346(13):995-1008.
32. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997 Apr 15;89(8):2689-2700.
33. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005 Sep 1;106(5):1532-1537. Epub 2005 May 5.
34. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000 Apr 15;95(8):2523-2529.
35. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007 Jan 2;146(1):25-33.
36. Zaja F, Baccarani M, Mazza P, et al. A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up. 50th ASH Annual Meeting and Exposition. American Society of Hematology, San Francisco, CA. December 7, 2008. https://ash.confex.com/ash/2008/webprogram/Paper8341.html. Accessed June 22, 2012.
37. Vancine-Califani SM, De Paula EV, Ozelo MC, Orsi FL, Fabri DR, Annichino-Bizzacchi JM. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets. 2008 Nov;19(7): 489-495.
38. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190-4207. Epub 2011 Feb 16.
39. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003 Feb;120(4):574-596.
40. Indian Academy of Pediatrics. IAP Guidelines 2006 on Diagnosis & Management of ITP in Children. 2006.